Ewa Fiorentino-Rozek on Blood Group Genotyping: Are We Ready for Routine Use?
Ewa Fiorentino-Rozek, Head of Clinical Affairs at AliveDx, shared a post on LinkedIn:
“IVD of the Week: Blood Group Genotyping – Are We Ready for Routine Use?
Blood group genotyping has come a long way in recent years. It started as a specialized tool for identifying rare donors and solving complex antibody cases, but it’s increasingly being talked about as part of routine blood bank practice.
Compared to traditional serology, genotyping can:
– Detect blood group variants that serology can miss
– Improve matching for patients who receive frequent transfusions (like those with sickle cell disease or thalassemia
– Help manage rare donor inventories more effectively
Yet despite all this progress, many labs still rely mostly on serological methods. Making genotyping a routine part of blood banking isn’t simple. There are real hurdles:
– Cost – both for instruments and ongoing reagents
– Integration – adapting workflows and training staff
– Data interpretation – translating genotyping results into clear transfusion decisions
– Guidelines – not all regions have clear recommendations on when or how to implement routine genotyping
I’d love to hear from colleagues across labs, blood services, and industry:
– Is your center already using genotyping routinely, or only for special cases?
– What barriers are slowing down broader adoption where you work?
– Do you think genotyping will become standard practice in the next five years—or is that still further off?
Let’s share real-world experiences and thoughts on how to bridge the gap between promise and practice in blood group genotyping.
________
Hi, I’m Ewa, and I help In Vitro Diagnostics companies bring innovative products to market.
Follow me for insights on IVD regulations, performance evaluation, and industry trends.”
Stay updated with Hemostasis Today.
-
Oct 30, 2025, 12:12Laura Ceci Galanos Reflects on WSC 2025
-
Oct 30, 2025, 03:53Michael Makris on Biomarin's Decision to Divest Roctavian
-
Oct 29, 2025, 10:39UMR1011 Researchers at ECTH 2025
-
Oct 29, 2025, 07:09Hritvik Jain and Andrew Goldsweig Sharedrisk About the Risk of MACCE, AMI, and readmission in IBD patients undergoing PCI
-
Oct 29, 2025, 07:07Flora Peyvandi Shared an Article About Menstrual Bleeding and Bleeding Tendency in Dutch Adolescents
-
Oct 30, 2025, 05:14Umberto Pensato on Reperfusion Outcomes in Stroke
-
Oct 29, 2025, 07:18Osimertinib Has Transformed Lung Cancer Care — But at What Cost to the Heart?
-
Oct 29, 2025, 07:15From the Lab to Prague․ Our ECTH 2025 Experience
-
Oct 29, 2025, 07:13Amol Akhade: Happy To Share Our Paper Published In Lancet Oncology
-
Oct 29, 2025, 07:09Davide Capodanno: This Time It’s About the Timing of Complete Revascularization in ACS
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Oct 27, 2025, 09:19Mitra Najafi: Digital Storage Device - Specifically Designed and Developed to Store and Preserve PRP
-
Oct 30, 2025, 11:56Lucas de Vries Defends His PHD Combining Physics, Deep Learning and Medical Imaging
-
Oct 30, 2025, 03:50Laura Bouvet Receives the Young Investigator Award at ECTH 2025
-
Oct 29, 2025, 08:30ECTH 2025․ Advancing the Science of Thrombosis and Haemostasis Together
-
Oct 28, 2025, 06:59Wim van den Broek Attended ECTH in Prague
-
Oct 28, 2025, 06:46Alexandre Kauskot Attended ECTH in Prague